Laden…
(3,4-dihydroxy-5-nitrophenyl)-(4-methylphenyl)methanone
Tolcapone is a selective and reversible inhibitor of the enzyme catechol-O-methyltransferase (COMT), used in the treatment of Parkinson's disease. It enhances dopaminergic neurotransmission by inhibiting dopamine degradation. Due to potential hepatotoxic effects, careful monitoring of liver function is required. Tolcapone is used as an adjunct to L-Dopa therapy to alleviate motor symptoms.
Class
COMT-Hemmer
Pharmacological context
Mechanism
Tolcapone wirkt als Hemmer des Enzyms Catechol-O-Methyltransferase...
Short read on known pharmacology
Interactions
No curated pairs visible
Curated visible combinations
Risk theme
Interpret risks carefully
Condensed from structured notes
Receptor Targets
Mechanism of Action
Designations
IUPAC: (3,4-dihydroxy-5-nitro-phenyl)-(p-tolyl)methanone
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Receptor Profile
Der Dopamintransporter (DAT) ist ein Natrium-abhängiger Monoamintransporter, der Dopamin aus dem synaptischen Spalt entfernt. Er ist ein zentrales Ziel von Stimulants und spielt eine Schlüsselrolle im Belohnungssystem.
Catechol-O-Methyltransferase (COMT) ist ein Enzym, das Katecholamine (Dopamin, Noradrenalin, Adrenalin) durch Methylierung inaktiviert. Der Val158Met-Polymorphismus beeinflusst die Enzymaktivität und kognitive Funktionen.
Substance Fingerprint
Pharmacological profile based on receptor binding, mechanism of action, and substance class. Limited data — interpret profile with caution.
Synapedia Evidence
Effects & Pharmacology is partially translated. Some details are still being expanded.
Tolcapone wirkt als Hemmer des Enzyms Catechol-O-Methyltransferase (COMT), was zu einer erhöhten Verfügbarkeit von Dopamin im zentralen Nervensystem führt.
Known Effects
Individual effects may vary significantly. These are pharmacologically documented effects.
Reported range 200 mg
Total duration 6–8 hours
Oral
| Tier | Dosage |
|---|---|
| Light | 100 mg |
| Reported | 200 mg |
| Strong | 300 mg |
Oral
Onset
1–2 hours
Peak
2–4 hours
Total duration
6–8 hours
Avoid uncertain dosage claims and do not infer numbers when data is unclear.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Summary
Mögliche Nebenwirkungen umfassen Leberfunktionsstörungen und gastrointestinalen Beschwerden.
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.